Does concomitant treatment with candesartan and metoprolol prevent early decline in global left ventricular function in patients treated for early breast cancer with adjuvant anthracycline-containing regimens?
Concomitant treatment with candesartan protects against early decline in left ventricular function in patients receiving anthracycline-containing regimens for early breast cancer.
In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function.
Gulati et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: